Delving into the Latest Updates on Atorvastatin Calcium/Fenofibrate with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

AtorFen, Atorvastatin/fenofibrate, LCP-AtorFen

Target

HMGCR x PPARα

Mechanism

HMG-CoA reductase inhibitors(HMG-CoA reductase inhibitors), PPARα agonists(Peroxisome proliferator-activated receptor α agonists)

Therapeutic Areas

Endocrinology and Metabolic Disease

Active Indication-

Inactive Indication

Diabetes Mellitus, Type 2Dyslipidemias

Originator Organization

Veloxis Pharmaceuticals A/S

Active Organization-

Inactive Organization

Laboratorios Silanes SA de CV

Veloxis Pharmaceuticals A/SLife Cycle Pharma A/S

Drug Highest PhasePendingPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC66H76CaF2N4O13

InChIKeyHIZONJHAVINWOX-NIJVSVLQSA-N

CAS Registry344423-98-9

View All Structures (2)

H0RSHOLM, Denmark--(BUSINESS WIRE)--LifeCycle Pharma A/S (OMX: LCP) (the “Company” or “LCP”), an emerging specialty pharmaceutical company, today announced that it has completed patient enrollment in its Phase II clinical trial of LCP-AtorFen for the treatment of mixed dyslipidemia, which commenced in July 2007 to compare LCP-AtorFen, the Company’s fixed-dose combination product candidate of atorvastatin and lowest dose fenofibrate, with Lipitor® (40 mg atorvastatin calcium tablets) and Tricor® (145mg fenofibrate tablets). In addition, the Company announced that it has initiated a 52-week, open-label extension study in order to capture additional safety and efficacy data on the use of LCP AtorFen in patients with mixed dyslipidemia.

Collaborate

100 Deals associated with Atorvastatin Calcium/Fenofibrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05769

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Diabetes Mellitus, Type 2	Phase 3	MX	Laboratorios Silanes SA de CV	15 Feb 2022
Dyslipidemias	Phase 3	US	Veloxis Pharmaceuticals A/S	01 Oct 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT00664859 (CTgov)	Phase 2/3	Dyslipidemias	140	LCP-AtorFen (LCP-AtorFen 40/100mg)	itmqdhvbop(qnhmyrknrl) = yqfkmxlmcv ynnbxbqlke (ciqydsfmzo, gttpmorhwl - yewagxtuxy) View more	-	24 Mar 2020
				Atorvastatin (Atorvastatin 40 mg)	itmqdhvbop(qnhmyrknrl) = zzdcihdzqt ynnbxbqlke (ciqydsfmzo, htozktwhse - mzodpfdjid) View more
NCT00504829 (CTgov)	Phase 2	Dyslipidemias	220	LCP-AtorFen (LCP-AtorFen 40/100mg)	mlgvtcustm(ezgxmmqjvk) = rzmavzgizc tblnjnxjpu (zymhooimda, nzusbrmqzf - undubddeyq) View more	-	05 Feb 2020
				Atorvastatin (Atorvastatin 40mg)	mlgvtcustm(ezgxmmqjvk) = bsxlgzxurj tblnjnxjpu (zymhooimda, oabtuaivde - kodwuiutnw) View more